JNJ

221.12

-0.62%↓

UNH

379.44

+2.66%↑

TMO

464.25

-1.7%↓

ISRG

449.79

-0.77%↓

ABT

84.24

-3.13%↓

JNJ

221.12

-0.62%↓

UNH

379.44

+2.66%↑

TMO

464.25

-1.7%↓

ISRG

449.79

-0.77%↓

ABT

84.24

-3.13%↓

JNJ

221.12

-0.62%↓

UNH

379.44

+2.66%↑

TMO

464.25

-1.7%↓

ISRG

449.79

-0.77%↓

ABT

84.24

-3.13%↓

JNJ

221.12

-0.62%↓

UNH

379.44

+2.66%↑

TMO

464.25

-1.7%↓

ISRG

449.79

-0.77%↓

ABT

84.24

-3.13%↓

JNJ

221.12

-0.62%↓

UNH

379.44

+2.66%↑

TMO

464.25

-1.7%↓

ISRG

449.79

-0.77%↓

ABT

84.24

-3.13%↓

Начало・Списък с акции・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Затворен

СекторЗдравеопазване

14.49 0.21

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.49

Максимум

14.49

Ключови измерители
By Trading Economics
Приходи	-16M 1.7M
Продажби	16M 185M
Марж на печалбата	0.912
Служители	511
EBITDA	-31M 16M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	61M 4.5B
Предишно отваряне	14.28
Предишно затваряне	14.49

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.925 / 7.38 Подкрепа & съпротива

Amicus Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.04.2026 г., 23:08 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 23:07 ч. UTC

Печалби

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:20 ч. UTC

Печалби

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After Gains on Wall Street -- Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30.04.2026 г., 23:27 ч. UTC

Пазарно говорене

Liontown Lithium Recovery Expected to Improve -- Market Talk

30.04.2026 г., 23:22 ч. UTC

Печалби

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30.04.2026 г., 22:52 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:33 ч. UTC

Печалби

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30.04.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30.04.2026 г., 22:05 ч. UTC

Печалби

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 21:57 ч. UTC

Печалби

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30.04.2026 г., 21:55 ч. UTC

Печалби

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30.04.2026 г., 21:53 ч. UTC

Печалби

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Сравнение с други в отрасъла

Ценова промяна

Amicus Therapeutics Inc Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Amicus Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.925 / 7.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Относно Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.